146 related articles for article (PubMed ID: 38302816)
1. The obeticholic acid can positively regulate the cancerous behavior of MCF7 breast cancer cell line.
Rahmani R; Eivazi N; Emamgholipour S; Aminian M; Jalilian A; Paknejad M
Mol Biol Rep; 2024 Feb; 51(1):250. PubMed ID: 38302816
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
3. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
[TBL] [Abstract][Full Text] [Related]
6. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid alleviate lipopolysaccharide-induced acute lung injury via its anti-inflammatory effects in mice.
Fei J; Fu L; Hu B; Chen YH; Zhao H; Xu DX; Li JB
Int Immunopharmacol; 2019 Jan; 66():177-184. PubMed ID: 30468885
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid differentially regulates hepatic injury and inflammation at different stages of D-galactosamine/lipopolysaccharide-evoked acute liver failure.
Ding W; Fan YY; Zhang C; Fu L; Chen X; Xu DX
Eur J Pharmacol; 2019 May; 850():150-157. PubMed ID: 30772394
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
[TBL] [Abstract][Full Text] [Related]
12. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
13. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis.
Zhou J; Huang N; Guo Y; Cui S; Ge C; He Q; Pan X; Wang G; Wang H; Hao H
Acta Pharm Sin B; 2019 May; 9(3):526-536. PubMed ID: 31193776
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
15. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
16. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
Wu H; Liu G; He Y; Da J; Xie B
Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
18. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model.
Olthof PB; Huisman F; Schaap FG; van Lienden KP; Bennink RJ; van Golen RF; Heger M; Verheij J; Jansen PL; Olde Damink SW; van Gulik TM
Br J Surg; 2017 Apr; 104(5):590-599. PubMed ID: 28195307
[TBL] [Abstract][Full Text] [Related]
19. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
Friedman ES; Li Y; Shen TD; Jiang J; Chau L; Adorini L; Babakhani F; Edwards J; Shapiro D; Zhao C; Carr RM; Bittinger K; Li H; Wu GD
Gastroenterology; 2018 Dec; 155(6):1741-1752.e5. PubMed ID: 30144429
[TBL] [Abstract][Full Text] [Related]
20. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]